重组CS6 ETEC疫苗在Aotus nancymaae猴攻毒模型中的免疫原性与保护效力评价
本研究在CS6阳性产肠毒素大肠杆菌(ETEC)B7A株攻毒的Aotus nancymaae非人灵长类模型中,评估重组CS6亚单位疫苗dscCssBA联合dmLT佐剂皮内接种的免疫原性与保护效力。结果显示疫苗接种诱导了针对CS6和LT的强血清抗体应答,攻毒后无腹泻发生(保护效力=100%,p=0.03),而PBS免疫组攻击率为62.5%。
要点
- dscCssBA+dmLT皮内接种诱导针对CS6和LT的强血清抗体应答。
- 攻毒后疫苗组无腹泻,保护效力100%(p=0.03),对照组攻击率62.5%。
- 重组CS6抗原值得进一步临床开发。
核心结论
- 重组dscCssBA抗原对同源CS6+ETEC株B7A攻毒提供保护,CS6应被考虑用于进一步临床开发。
研究设计与样本
- 在Aotus nancymaae非人灵长类ETEC攻毒模型中,用CS6+ETEC株B7A测试重组CS6亚单位疫苗dscCssBA联合dmLT皮内接种的免疫原性与保护效力。
主要发现
- dscCssBA+dmLT皮内接种诱导针对CS6和LT的强血清抗体应答。
- B7A攻毒后疫苗组无腹泻发生,保护效力=100%(p=0.03),PBS免疫组攻击率为62.5%。
关键数值与推荐
- 保护效力=100%(p=0.03),对照组攻击率62.5%。
临床怎么用
- 提示重组CS6抗原可作为ETEC疫苗候选进入进一步临床开发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Colonization factors or Coli surface antigens (CFs or CS) are important virulence factors of Enterotoxigenic E. coli (ETEC) that mediate intestinal colonization and accordingly are targets of vaccine development efforts. CS6 is a highly prevalent CF associated with symptomatic ETEC infection both in endemic populations and amongst travelers. In this study, we used an Aotus nancymaae non-human primate ETEC challenge model with a CS6 + ETEC strain, B7A, to test the immunogenicity and protective efficacy (PE) of a recombinant CS6-based subunit vaccine. Specifically, we determined the ability of dscCssBA, the donor strand complemented recombinant stabilized fusion of the two subunits of the CS6 fimbriae, CssA and CssB, to elicit protection against CS6 + ETEC mediated diarrhea when given intradermally (ID) with the genetically attenuated double mutant heat-labile enterotoxin LT(R192G/L211A) (dmLT). ID vaccination with dscCssBA + dmLT induced strong serum antibody responses against CS6 and LT. Importantly, vaccination with dscCssBA + dmLT resulted in no observed diarrheal disease (PE = 100%, p = 0.03) following B7A challenge as compared to PBS immunized animals, with an attack rate of 62.5%. These data demonstrate the potential role that CS6 may play in ETEC infection and that recombinant dscCssBA antigen can provide protection against challenge with the homologous CS6 + ETEC strain, B7A, in the Aotus nancymaae diarrheal challenge model. Combined, these data indicate that CS6, and more specifically, a recombinant engineered derivative should be considered for further clinical development.
引用
- Ramakrishnan A, Joseph SS, Reynolds ND, et al. Evaluation of the immunogenicity and protective efficacy of a recombinant CS6-based ETEC vaccine in an Aotus nancymaae CS6 + ETEC challenge model. Vaccine. 2020. PMID: 33357957. doi:10.1016/j.vaccine.2020.12.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。